Darusentan (Abbott Laboratories)

Research output: Contribution to journalReview article

Authors

Abstract

Abbott (formerly Knoll) is developing darusentan, an endothelin A antagonist, as a potential treatment for congestive heart failure (CHF) [398274]. The compound entered phase II trials in December 1998 [310187]. In a model of monocrotaline-induced pulmonary hypertension, darusentan (50 mg/kg/day), significantly reduced right ventricular systolic pressure, and in a canine model of CHF chronic treatment for 2 weeks significantly reduced left ventricular end diastolic pressure, mean pulmonary artery pressure, and right atrial pressure. Darusentan is a selective antagonist in vitro (ET(A): K(i) = 1.4 nM; ET(B): K(i) = 184 nM) [339872].

Details

Original languageEnglish
Pages (from-to)1284-92
Number of pages9
JournalI Drugs: The Investigational Drugs Journal
Volume4
Issue number11
Publication statusPublished - 1 Nov 2001